Elicera Therapeutics AB (SE:ELIC)
:ELIC
Want to see SE:ELIC full AI Analyst Report?
Total Valuation
Elicera Therapeutics AB has a market cap or net worth of kr162.11M. The enterprise value is kr135.51M.
Market Capkr162.11M
Enterprise Valuekr135.51M
Share Statistics
Elicera Therapeutics AB has 48,535,545 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,535,545
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Elicera Therapeutics AB’s return on equity (ROE) is -0.75 and return on invested capital (ROIC) is -76.81%.
Return on Equity (ROE)-0.75
Return on Assets (ROA)-0.63
Return on Invested Capital (ROIC)-76.81%
Return on Capital Employed (ROCE)-0.77
Revenue Per Employee0.00
Profits Per Employee-8.97M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Elicera Therapeutics AB is ―. Elicera Therapeutics AB’s PEG ratio is 0.54.
PE Ratio―
PS Ratio0.00
PB Ratio10.19
Price to Fair Value10.19
Price to FCF-11.04
Price to Operating Cash Flow-7.52
PEG Ratio0.54
Income Statement
In the last 12 months, Elicera Therapeutics AB had revenue of 0.00 and earned -17.41M in profits. Earnings per share was -0.38.
Revenue0.00
Gross Profit0.00
Operating Income-17.94M
Pretax Income-17.41M
Net Income-17.41M
EBITDA-17.40M
Earnings Per Share (EPS)-0.38
Cash Flow
In the last 12 months, operating cash flow was -21.55M and capital expenditures 0.00, giving a free cash flow of -21.55M billion.
Operating Cash Flow-21.55M
Free Cash Flow-21.55M
Free Cash Flow per Share-0.44
Dividends & Yields
Elicera Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.04
52-Week Price Change-21.23%
50-Day Moving Average5.58
200-Day Moving Average5.84
Relative Strength Index (RSI)43.12
Average Volume (3m)134.24K
Important Dates
Elicera Therapeutics AB upcoming earnings date is Aug 27, 2026, Before Open (Confirmed).
Last Earnings DateApr 28, 2026
Next Earnings DateAug 27, 2026
Ex-Dividend Date―
Financial Position
Elicera Therapeutics AB as a current ratio of 6.75, with Debt / Equity ratio of 0.00%
Current Ratio6.75
Quick Ratio6.75
Debt to Market Cap0.00
Net Debt to EBITDA1.43
Interest Coverage Ratio-2.28K
Taxes
In the past 12 months, Elicera Therapeutics AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Elicera Therapeutics AB EV to EBITDA ratio is -12.25, with an EV/FCF ratio of -9.89.
EV to Sales0.00
EV to EBITDA-12.25
EV to Free Cash Flow-9.89
EV to Operating Cash Flow-9.89
Balance Sheet
Elicera Therapeutics AB has kr24.85M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr24.85M billion.
Cash & Marketable Securitieskr24.85M
Total Debtkr0.00
Net Cashkr24.85M
Net Cash Per Sharekr0.51
Tangible Book Value Per Sharekr0.51
Margins
Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin100.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Elicera Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast43.31%